On March 30, 2022, Mr. Brady Johnson provided Cidara Therapeutics, Inc. with notice of his intent to resign from his position as the principal accounting officer of the Company, effective April 15, 2022. Mr. Johnson's resignation is not a result of any disagreement with the Company or its Board of Directors, or any matter relating to its operations, policies or practices. Mr. Johnson resigned from the Company to pursue other opportunities.

Effective as of the date of Mr. Johnson's resignation, Preetam Shah, Ph.D., MBA, Chief Financial Officer and Chief Business Officer of the Company, will assume the role of the Company's principal accounting officer.